This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
BHC Q2 Earnings Beat Estimates on Salix and Solta Growth, '26 View Raised
by Zacks Equity Research
BHC beats Q2 estimates as Salix, Solta Medical and Bausch + Lomb fuel growth, lifting 2026 revenue and EBITDA guidance after strong earnings.
BHCPositive Net Change AMRNPositive Net Change LQDANegative Net Change HRMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron Q2 Earnings Beat, Sales Up on Dupixent & Eylea HD Strength
by Zacks Equity Research
REGN's Q2 earnings and revenues beat estimates as robust Eylea HD demand and higher Dupixent profits offset declining Eylea sales.
REGNPositive Net Change SNYPositive Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
by Zacks Equity Research
uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130 and a cash runway into 2030 keep its pipeline in focus.
QUREPositive Net Change NBIXNegative Net Change LQDANegative Net Change HRMYNegative Net Change
biotechnology biotechs medical
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
by Zacks Equity Research
AMRN surpasses Q2 earnings estimates despite lower revenues, as cost cuts, rising demand and global partner-driven growth shape its ongoing transformation.
AMRNPositive Net Change NBIXNegative Net Change LQDANegative Net Change HRMYNegative Net Change
biotechs
Moderna Q2 Earnings Loom: Buy or Sell the Stock Ahead of Results?
by Sundeep Ganoria
MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.
MRNANegative Net Change GSKNegative Net Change PFEPositive Net Change MRKPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up
by Zacks Equity Research
RGEN tops Q2 earnings and revenue estimates, lifts its 2026 revenue and EPS outlook, and sees shares jump after stronger-than-expected results.
RGENNegative Net Change LQDANegative Net Change HRMYNegative Net Change
biotechs earnings
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan
by Zacks Equity Research
GSK beats Q2 earnings and revenue estimates, reaffirms 2026 guidance and unveils a new cost-saving plan.
GSKNegative Net Change JNJPositive Net Change LQDANegative Net Change HRMYNegative Net Change
biotechs earnings
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?
by Ahan Chakraborty
Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead to Report Q2 Earnings: How Should You Play the Stock Now?
by Zacks Equity Research
GILD heads into Q2 earnings with HIV franchise strength, rising Yeztugo expectations and oncology progress, even as Cell Therapy faces competitive pressure.
GILDNegative Net Change GSKNegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?
by Sundeep Ganoria
AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.
ABBVNegative Net Change RHHBYNegative Net Change JNJPositive Net Change
biotechs earnings-preview medical pharmaceuticals